Anika Therapeutics (ANIK) EBITDA Margin Growth (3y) (2013 - 2026)
Anika Therapeutics (ANIK) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | 1,725.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,725.00 |
| Mar 31, 2026 | 1,457.00 |
| Dec 31, 2025 | 59,066.00 |
| Sep 30, 2025 | 278.00 |
| Jun 30, 2025 | -629.00 |
| Mar 31, 2025 | -669.00 |
| Dec 31, 2024 | 2,316.00 |
| Sep 30, 2024 | -356.00 |
| Jun 30, 2024 | -2,996.00 |
| Mar 31, 2024 | -1,230.00 |
| Dec 31, 2023 | -79,716.00 |
| Sep 30, 2023 | 650.00 |
| Jun 30, 2023 | 2,289.00 |
| Mar 31, 2023 | -5,314.00 |
| Dec 31, 2022 | -60,468.00 |
| Sep 30, 2022 | -5,497.00 |
| Jun 30, 2022 | -4,770.00 |
| Mar 31, 2022 | -3,186.00 |
| Dec 31, 2021 | -6,168.00 |
| Sep 30, 2021 | -2,872.00 |